American Epilepsy Society Annual Meeting (AES)

Patients were more affected by seizure cluster control and need for additional midazolam dosing than post-dose somnolence.

Patients treated with NeuroPace’s Responsive Neurostimulation system within 20 years of epilepsy onset were observed to have significantly better outcomes related to several aspects of quality of life and mood compared to those treated later.

The director of pediatric epilepsy and the Herscot Center for Tuberous Sclerosis Complex at Massachusetts General Hospital, and professor of neurology at Harvard Medical School spoke to the safety outcomes from GWPCARE6 and CBD’s low-dose efficacy.

Study findings suggest that the presence of hypsarrhythmia—abnormal, chaotic brainwave patterns—may play a role in the risk of autism spectrum disorder in patients with a history of infantile spasms.

The medical director of the Comprehensive Epilepsy Clinic at Nicklaus Children’s Hospital discussed the advantages of intranasal diazepam over traditional midazolam and rectal diazepam.

Data suggests that treatment with cannabidiol is associated with other benefits besides a decrease in seizure frequency.

The assistant professor of psychology at East Carolina University offered insight about the resources are available to physicians and providers and what techniques can be useful to help patients have a better quality of life in light of refractory and uncontrolled seizures.

Adjunctive cenobamate demonstrated a good tolerability and safety profile, as well as sustained efficacy, in patients with uncontrolled focal seizures.

In a PROVE study subgroup of adolescent patients exposed to perampanel over a 2-year period, the Eisai product proved to be well-tolerated and efficacious, with good retention rates.

The director of epilepsy surgery and associate professor of neurosurgery at UC Irvine spoke about the consequences of patients choosing to forgo beneficial surgery and the importance of communication between surgeon and epileptologist.

Interim analysis of a 5-year, post-approval study of the NeuroPace Responsive Neurostimulation system support prior findings that the device is safe and effective in reducing medically intractable focal seizures in adults.

Fenfluramine oral solution is currently being evaluated by the FDA for the treatment of seizures associated with Dravet syndrome.

A single-center study of more than 3600 virtual visits displayed a high level of satisfaction from patients regarding their experience with telemedicine and their providers, suggesting the practice may be ready for large-scale use.

Patients treated with intranasal midazolam who were on enzyme-inducing AEDs experienced numerically lower treatment-emergent adverse events.

The director of epilepsy surgery and associate professor of neurosurgery at UC Irvine discussed the challenges he has encountered in getting patients with epilepsy to undergo beneficial procedures, often due to misinformation.

The director of pediatric epilepsy and the Herscot Center for Tuberous Sclerosis Complex at Massachusetts General Hospital, and professor of neurology at Harvard Medical School discussed the findings of the GWPCARE6 trial of cannabidiol.

The American Epilepsy Society recognized several members from its clinical and research communities for their outstanding contributions to the field of epilepsy.

Despite evidence of the benefits and safety of breastfeeding in women with epilepsy, 2 studies suggest this population breastfeeds significantly less often than women without epilepsy, due to fears of drug exposure or recommendations against the practice.

An analysis of 2 different doses of intranasal diazepam showed consistent safety and tolerability results for repeat dosing

The professor and chief of pediatric neurology, and director of the comprehensive epilepsy program and neuroscience institute at Le Bonheur Children’s Hospital offered insight into his experience with midazolam and its potential to play a vital role in treating seizure clusters.

Patients who were treated with cannabidiol 25 mg or 50 mg experienced seizure reductions of 49% and 48%, respectively, nearly double that of the placebo group, which experienced reductions of 27%.

NeurologyLive will be providing live coverage of AES 2019 from Baltimore beginning Saturday, December 7.

Mind Moments® a podcast from NeurologyLive®, brings you exclusive interviews with experts in neurologic disorders.

Despite accessibility to antiepileptic drugs in high-income settings, more than one-third of patients with newly diagnosed epilepsy were not treated or had delayed treatment.

The director of the Pediatric Epilepsy Center at UCSF Benioff Children’s Hospital discussed the efficacy profile of ZX008, for which Zogenix recently submitted a new drug application to the FDA for the treatment of Dravet syndrome.

The neurologist and epileptologist at the Mayo Clinic in Jacksonville discussed when to best perform routine EEG in patients with epilepsy.

The attending neurologist at Brigham and Women's Hospital spoke about data from an analysis that concluded that women with frontal lobe epilepsy are more likely to experience a worsening of their seizure frequency during pregnancy.

The pediatric epileptologist at Nicklaus Children’s Hospital discussed the long-term seizure freedom data that looked at the effectiveness of perampanel which demonstrated a gratifying response in seizure control for patients with secondarily generalized seizures.

The neurologist and epileptologist at the Mayo Clinic in Jacksonville spoke about how to best identify adult patients in need of routine EEG and what it will bring to the table relative to the clinician.

The Director of the Pediatric Epilepsy Center at UCSF Benioff Children's Hospital spoke about what defines a "clinically meaningful change in seizure frequency" using data from a phase 3 clinical trial of ZX008 for the adjunctive treatment of seizures associated with Dravet syndrome.